Engineered extracellular vesicles as “supply vehicles” to alleviate type 1 diabetes

Abstract

Recent findings have indicated that the deficiency of inhibitory programmed cell death ligand 1 (PD-L1) and galectin-9 (Gal-9) in pancreatic β-cells is associated with the progression of type 1 diabetes (T1D). This suggests that exogenous PD-L1 and Gal-9 may have promising potential as therapeutics for the treatment of T1D. In light of these reports, a recent work investigated the potential of artificial extracellular vesicles (aEVs) with the presentation of PD-L1 and Gal-9 ligands (PD-L1–Gal-9 aEVs) as a treatment for T1D, with the findings published in Diabetes. Notably, the PD-L1–Gal-9 aEVs demonstrated the capacity to induce apoptosis of T cells and the formation of regulatory T (Treg) cells, thereby maintaining immune tolerance. Furthermore, the in vivo administration of PD-L1–Gal-9 aEVs resulted in a reduction in T cell infiltration in the pancreas, an increase in β-cell integrity protection, a significant decrease in blood glucose levels, and a delay in the progression of T1D. In conclusion, this study proposed an innovative approach to the treatment of T1D progression through the use of immunosuppressive EVs. This highlight provides a comprehensive analysis and discussion of the pivotal findings of this study.

Keywords

Extracellular vesicles / type 1 diabetes / PD-L1 / Gal-9 / hyperglycemia

References

[1] Roep BO,van Tienhoven R.Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?).Nat Rev Endocrinol2021;17:150-61 PMCID:PMC7722981

[2] Zhang J,Jin S.The pharmacology and therapeutic role of cannabidiol in diabetes.Exploration2023;3:20230047 PMCID:PMC10582612

[3] Mobasseri M,Amiri T,Hosseini Fard H.Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis.Health Promot Perspect2020;10:98-115 PMCID:PMC7146037

[4] Li Y,Yue TT.Revisiting the antigen-presenting function of β cells in T1D pathogenesis.Front Immunol2021;12:690783 PMCID:PMC8318689

[5] Wilcox G.Insulin and insulin resistance.Clin Biochem Rev2005;26:19 PMCID:PMC1204764

[6] Primavera R,Swaminathan G.Emerging nano- and micro-technologies used in the treatment of type-1 diabetes.Nanomaterials2020;10:789 PMCID:PMC7221526

[7] Liu J,Lyu Q,Wang W.Targeted protein delivery based on stimuli-triggered nanomedicine.Exploration2024;4:20230025 PMCID:PMC11189579

[8] Lernmark A.Immune therapy in type 1 diabetes mellitus.Nat Rev Endocrinol2013;9:92-103

[9] Goldman JD.Teplizumab: the first treatment to delay the progression of type 1 diabetes.Clin Diabetes2023;41:474-6 PMCID:PMC10338277

[10] Veiseh O,Whitehead KA,Langer R.Managing diabetes with nanomedicine: challenges and opportunities.Nat Rev Drug Discov2015;14:45-57 PMCID:PMC4751590

[11] Jing Z,Ma Y,Liang X.Leverage biomaterials to modulate immunity for type 1 diabetes.Front Immunol2022;13:997287 PMCID:PMC9667795

[12] Feng C,Nie G.Biomimetic and bioinspired nano-platforms for cancer vaccine development.Exploration2023;3:20210263 PMCID:PMC10624393

[13] Dai H,Wang C.Recent applications of immunomodulatory biomaterials for disease immunotherapy.Exploration2022;2:20210157 PMCID:PMC10191059

[14] Zhang K.Stem cell-derived exosome versus stem cell therapy.Nat Rev Bioeng2023;Online ahead of print: PMCID:PMC10092910

[15] Cheng K.Guidelines for clinical translation and commercialization of extracellular vesicles and exosomes based therapeutics.Extracellular Vesicle2023;2:100029

[16] Li L,Zhu D,Cheng K.Engineering exosomes and exosome-like nanovesicles for improving tissue targeting and retention.Fundamental Research2024;Online ahead of print:

[17] Zhu D.Cardiac cell therapy for heart repair: should the cells be left out?.Cells2021;10:641 PMCID:PMC7999733

[18] Ding Y,Hu Q.Recent advances in overcoming barriers to cell-based delivery systems for cancer immunotherapy.Exploration2022;2:20210106 PMCID:PMC10190958

[19] Soltani S,Emami Aleagha MS.Extracellular vesicle therapy for type 1 diabetes.Front Immunol2022;13:865782 PMCID:PMC9024141

[20] Sabry D,Zakaria R,Samir M.The effect of exosomes derived from mesenchymal stem cells in the treatment of induced type 1 diabetes mellitus in rats.Biotechnol Lett2020;42:1597-610

[21] Cantaluppi V,Figliolini F.Microvesicles derived from endothelial progenitor cells enhance neoangiogenesis of human pancreatic islets.Cell Transplant2012;21:1305-20

[22] Liu M,Yan N,Cheng K.Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity.Nat Nanotechnol2024;19:565-75

[23] Liu H,Zhang M.Mesenchymal stem cell derived exosomes repair uterine injury by targeting transforming growth factor-β signaling.ACS Nano2024;18:3509-19

[24] Popowski KD,George A.Inhalable exosomes outperform liposomes as mRNA and protein drug carriers to the lung.Extracell Vesicle2022;1:100002 PMCID:PMC9213043

[25] Zhu D,Huang K.Intrapericardial exosome therapy dampens cardiac injury via activating Foxo3.Circ Res2022;131:e135-50 PMCID:PMC9667926

[26] Wang Z,Zhu D.Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine.Nat Biomed Eng2022;6:791-805 PMCID:PMC10782831

[27] Popowski KD,George A,Cheng K.Exosome therapeutics for COVID-19 and respiratory viruses.View2021;2:20200186 PMCID:PMC7995024

[28] Fan M,Shen D.Decoy exosomes offer protection against chemotherapy-induced toxicity.Adv Sci2022;9:e2203505 PMCID:PMC9661835

[29] Ding JT,Lin KL,Zou F.Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes.Front Endocrinol2022;13:1090842 PMCID:PMC9871554

[30] Yang Z,Li L.Bioengineered artificial extracellular vesicles presenting PD-L1 and Gal-9 ameliorate new-onset type 1 diabetes.Diabetes2024;73:1325-35